Life sciences job openings · Updated 2026-08-01
GSK to acquire Nuvalent for $10.6B; cash offer of $124 per share
GSK to acquire Nuvalent for ~$10.6B cash; gains zidesamtinib and ALK/ROS1 assets
News sourced from public life sciences media. Not affiliated with these publications.
Company description, mission, culture, and benefits — visible after this page is claimed and verified.
Sign up free to search all 0+ openings with AI-powered matching.
Search Nuvalent JobsProfile generated from publicly available hiring data.
·Are you Nuvalent? Claim this page or contact us